Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size
Autor: | Berrylin J. Ferguson, Gregory Hebrank, Don Archibald, Michael E. Bozik, Mary C. Sullivan, Tanya M. Laidlaw, Calman Prussin, Andrew P. Lane, Steven I. Dworetzky, Marina L. Palumbo, Reynold A. Panettieri, Nithin D. Adappa, Stella E. Lee |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
medicine.medical_specialty business.industry respiratory system Eosinophil medicine.disease Gastroenterology 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure 030228 respiratory system Otorhinolaryngology Internal medicine medicine Clinical endpoint Eosinophilia Nasal polyps Amyotrophic lateral sclerosis medicine.symptom Adverse effect business Dexpramipexole medicine.drug Respiratory tract |
Zdroj: | The Laryngoscope. 129:E61-E66 |
ISSN: | 0023-852X |
Popis: | OBJECTIVE Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia is a disease of the upper respiratory tract for which few therapies are available. Because the oral investigational drug dexpramipexole serendipitously decreased blood eosinophils in amyotrophic lateral sclerosis studies, we assessed its safety, eosinophil-lowering activity, and preliminary clinical efficacy in patients with CRSwNP and eosinophilia. METHODS Sixteen subjects with CRSwNP, absolute eosinophil count (AEC) ≥ 0.300 × 109 /L, and polyp tissue eosinophils were evaluable for efficacy in a 6-month open-label, multi-center study of dexpramipexole 150 mg twice daily. The coprimary endpoints were change in AEC and change in total polyp score (TPS) from baseline to month 6, with additional clinical and histologic endpoints assessed. RESULTS Thirteen of 16 subjects completed 6 months of dexpramipexole treatment. Geometric mean baseline AEC was 0.525 ± 0.465 eosinophils × 109 /L and decreased to 0.031 ± 0.019 after 6 months of dexpramipexole treatment, a 94% reduction (P |
Databáze: | OpenAIRE |
Externí odkaz: |